Status: Recruiting
HP007 Monotherapy for Relapsed or Refractory Advanced Solid Tumors
This study is an open-label, dose-escalation and expansion, Phase I clinical study to evaluate the safety, tolerability, PK characteristics and preliminary antitumor activity of HP007 monotherapy in patients with advanced malignant solid tumors.
Participants needed: 44
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Parr Biotechnology (Hebei) Co., Ltd.Updated: Sep 23, 2026Locations: 1
Eligibility criteria
Male/female, 18-75 years inclusive. [+8]
Past/current medical conditions [+28]